New CDER Impact Story on Physiologically Based Pharmacokinetic Modeling of Sertraline Dosing in Pregnancy - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. Physiologically Based Pharmacokinetic Modeling of Sertraline Dosing in Pregnancy Pregnant women are a special and vulnerable population with respect to drug therapy but have often been excluded from clinical trials. CDER researchers and NCTR collaborators are working to develop quantitative predictive modeling tools to ensure that drug treatment during pregnancy maximizes maternal therapeutic benefit while minimizing fetal risk. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA